GLP-1受体激动剂对2型糖尿病大鼠糖脂代谢和小肠L细胞功能的影响

目的研究胰高血糖素样肽1（GLP-1）受体激动剂对2型糖尿病大鼠小肠L细胞GLP-1表达的影响。方法观察正常大鼠和2型糖尿病大鼠经GLP-1受体激动剂Exenatide干预前后体质量、空腹血糖、血脂谱、空腹胰岛素、胰岛素抵抗指数和胰岛素敏感指数的变化，免疫组织化学方法检测大鼠小肠L细胞GLP-1的表达变化。结果与糖尿病组比较，糖尿病Exenatide干预组大鼠的体质量、空腹血糖、空腹胰岛素、血脂谱、胰岛素抵抗指均有明显改善，差异有统计学意义（P〈0．05）。糖尿病组和糖尿病Exenatide干预组大鼠小肠L细胞GLP-1的表达均显著低于正常对照组（P〈0．0l，P〈0．05）；与糖尿病组比较，糖尿病Exenatide干预组大鼠小肠L细胞GLP-1的表达显著升高（P〈0．05）。结论GLP-1受体激动剂可能对改善糖尿病大鼠小肠I．细胞GLP-1表达功能有-定作用。

Effects of glucagon-like peptide-1 receptor agonist on glucose and lipid metabolism and function of intestinal L cells in type 2 diabetic rats

Objective To study the effects of glucagon-like peptide-1 （GLP-1） receptor agonist on GLP-1 expression in intestinal L cells of type 2 diabetic rats. Methods The changes of body weight, fasting glucose, lipid profile, fasting insulin, insulin resistance index, and insulin sensitivity index were observed in normal rats （normal group）, diabetic rats （ diabetic group）, and diabetic rats treated with GLP-1 receptor agonist （Exenatide treated group）. Expressions of GLP-1 in intestinal L cells were determined by immunohistochemical method. Results Compared to diabetic group, body weight, fasting glucose, lipid profiles, fasting insulin, lipid profile, and insulin resistance index significantly improved in Exenatide treated group （P 〈 0.05）. Compared to normal group, expressions of GLP-1 were significantly lower both in diabetic group and Exenatide treated group （P 〈 0.01, P 〈 0.05）, whereas the expression of GLP-1 of Exenatide treated group was higher than that of diabetic group （P 〈 0.05）. Conclusion GLP-1 receptor agonist may improve GLP-1 expression in intestinal L cells in type 2 diabetic rats.